Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1 Rheumatoid Arthritis, Systemic Juvenile 1 Rectal Neoplasms 1 Periodic Fevers Syndrome 1 Neoplasms 1 Mevalonate Kinase Deficiency 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Melanoma 1 Lung Neoplasms 1 Intestinal Neoplasms 1 Cryopyrin-Associated Periodic Syndromes 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Ductal 1 Bronchiolitis Obliterans Syndrome 1 Breast Neoplasms 1 Arthritis, Juvenile 1 Arthralgia 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

Sunitinib 86 Sorafenib 60 Everolimus 47 pazopanib 46 Bevacizumab 46 Nivolumab 44 pembrolizumab 37 aldesleukin 29 Interferon-alpha 26 Axitinib 24 temsirolimus 23 cabozantinib 20 Interleukin-2 19 Ipilimumab 16 Interferon alpha-2 15 Cyclophosphamide 15 fludarabine phosphate 14 Gemcitabine 14 Peripheral Blood Stem Cell Transplantation 11 Sirolimus 10 Paclitaxel 10 Erlotinib Hydrochloride 10 avelumab 8 Radiosurgery 8 Docetaxel 8 Cyclosporine 8 Capecitabine 8 tremelimumab 7 lenvatinib 7 Mycophenolic Acid 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Renal Cell × canakinumab × Clear all

NCT04028245 2026-04-15

SPARC-1

Columbia University

Phase EARLY_PHASE1 Completed

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡